AnmeldenAbmelden ProdukteTherapiegebieteDigitale AnwendungenService & RessourcenService & RessourcenFortbildungen & CMEServicematerialNewsKontakt


  1. (abgerufen am 09.07.2019)
  2. Maertens JA, Raad II, Marr KA et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other fi lamentous fungi (SECURE): a phase 3, Randomised-controlled, non-inferiority trial. Lancet 2016;387(10020):760-769.
  3. Lanternier F, Dannaoui E, Morizot G, Elie C, Garcia-Hermoso D, Huerre M, Bitar D, Dromer F, Lortholary O; French Mycosis Study Group. A global analysis of mucormycosis in France: the RetroZygo Study (2005–2007). Clin Infect Dis 2012a; 54(Suppl 1):S35–43
  4. Rüping MJ, Heinz WJ, Kindo AJ, Rickerts V, Lass-Flörl C, Beisel C, Herbrecht R, Roth Y, Silling G, Ullmann AJ, Borchert K, Egerer G, Maertens J, Maschmeyer G, Simon A, Wattad M, Fischer G, Vehreschild JJ, Cornely OA. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother 2010;65(2):296–302
  5. Skiada A, Lanternier F, Groll AH, Pagano L, Zimmerli S, Herbrecht R, Lortholary O, Petrikkos GL; European Conferen- ce on Infections in Leukemia. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica 2013;98(4):492–504
  6. Skiada A, Pagano L, Groll A, Zimmerli S, Dupont B, Lagrou K, Lass-Flörl C, Bouza E, Klimko N, Gaustad P, Richardson M, Hamal P, Akova M, Meis JF, Rodriguez-Tudela JL, Roilides E, Mitrousia-Ziouva A, Petrikkos G; European Confederation of Medical Mycology Working Group on Zygomycosis. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 2011;17(12):1859–1867
  7. Cox GM, Kauffman CA, Thomer AR. Mucormycosis (zygomycosis). In: Post T (Hrsg.). UpToDate. Waltham, Mass.: UpToDate; 2017. Abgerufen am 2. August 2017.
  8. Dagenais TR, Keller NP. Pathogenesis of Aspergillus fumiga- tus in Invasive Aspergillosis. Clin Microbiol Rev 2009;22(3):447–465
  9. Maschmeyer G, Haas A, Cornely OA. Invasive aspergillosis: epidemiology, diagnosis and management in immunocom- promised patients. Drugs 2007;67(11):1567–1601
  10. Ibrahim AS, Spellberg B, Walsh TJ et al. Pathogenesis of mucormycosis. Clin Infect Dis. 2012;54 Suppl 1:S16–S22.
  11. Spellberg B, Edwards Jr J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18:556–569.
  12. Lanternier F, Sun HY, Ribaud P, Singh N, Kontoyiannis DP, Lortholary O. Mucormycosis in organ and stem cell trans- plant recipients. Clin Infect Dis 2012b;54(11):1629–1636
  13. Ostrosky-Zeichner L, Al-Obaidi M. Invasive Fungal Infections in the Intensive Care Unit. Infect Dis Clin North Am 2017;31(3):475–487
  14. Bassetti M et. Al. Intensive care medicine research agenda on invasive fungal infection in critically ill patients. Intensiv Care Med. 2017; 43: 1225-1238
  15. Ku YH et al. Higher mortality of severe influenza patients with probable aspergillosis than those with and without other coinfections. J Formos Med Assoc. 2017 Sep;116(9):660-670
  16. Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young JA, Bennett JE. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016;63(4):e1–60
  17. Tsitsikas DA et al. Impact of the revised (2008) EORTC/MSG definitions for invasive fungal disease on the rates of diagnosis of invasive aspergillosis. Med Mycol 2012;50:538-42.
  18. Cornely OA et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect 2014;20 Suppl 3:5-26.
  19. Chamilos G, Luna M, Lewis RE, Bodey GP, Chemaly R, Tarrand JJ, Safdar A, Raad II, Kontoyiannis DP. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989–2003). Haematologica 2006;91(7): 986–989
  20. Chamilos G et al. Delaying amphotericin B–based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47:503-9.
  21. Pagano L et al. Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. J Antimicrob Chemother 2011;66 Suppl 1:i5-14.
  22. Walsh TJ et al. Treatment of Aspergillosis: Clinical
  23. Roden MM et al. Epidemiology and Outcome of Zygomycosis: A Review of 929  Reported Cases. Clin Infect Dis 2005;41:634-53.
  24. Dimopoulos G et al. How to select an antifungal agent in critically ill patients. J Crit Care 2013;28:717-27.
  25. Azie N et al. The PATH (Prospective Antifungal Therapy) Alliance® registry and invasive fungal infections: update 2012.
    Diagn Microb Infecti Dis 2012;73:293-300.
  26. (abgerufen am 09.07.2019)
  27. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and Clinical Manifestations of Mucormycosis. Clin Infect Dis 2012;54(Suppl 1):S23–34 
  28. Schauwvlieghe AFAD et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med. 2018 Oct;6(10):782-792. 
  29. Dignani MC. Epidemiology of invasive fungal diseases on the basis of autopsy reports. F1000Prime Rep 2014;6:81 
  30. Spellberg B, Walsh TJ, Kontoyiannis DP et al. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis. 2009;48(12):1743–1751.
  31. Morace G, Borghi E. Invasive mold infections: virulence and pathogenesis of mucorales. Int J Microbiol. 2012;1–5. 
  32. Chakrabarti A, Chatterjee SS, Das A et al. Invasive zygomycosis in India: experience in a tertiary care hospital. Postgrad Med J. 2009;85:573–581. 

Zurück zur Übersicht

PfizerPro bietet als Service- und Informationsportal für den medizinischen Fachkreis wissenschaftliche Inhalte, CME zertifizierte Fortbildungen sowie Service für Fachkreise und deren Patient:innen.


Copyright © 2024 Pfizer Pharma. Alle Rechte vorbehalten.
Mitglied im Verband der forschenden Pharma-Unternehmen und im Verein Freiwillige Selbstkontrolle für die Arzneimittelindustrie e.V.

Sie verlassen jetzt

Sie verlassen jetzt eine von Pfizer betriebene Webseite. Die Links zu allen externen Webseiten werden als Information für unsere Besucher bereitgestellt. Pfizer übernimmt keine Verantwortung für den Inhalt von Webseiten, die nicht zu Pfizer gehören und nicht von Pfizer betrieben werden.